Related references
Note: Only part of the references are listed.The BCL-2 Family Reunion
Jerry E. Chipuk et al.
MOLECULAR CELL (2010)
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Nageatte Ibrahim et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Expression, purification and use of recombinant annexin V for the detection of apoptotic cells
Susan E. Logue et al.
NATURE PROTOCOLS (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside
Thomas L. Hocker et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins
Jerry E. Chipuk et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?
Jerry E. Chipuk et al.
TRENDS IN CELL BIOLOGY (2008)
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai
NATURE REVIEWS CANCER (2008)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
BH3 domains of BH3-only proteins differentially regulate bax-mediated mitochondrial membrane permeabilization both directly and indirectly
T Kuwana et al.
MOLECULAR CELL (2005)
Accessing key steps of human tumor progression in vivo by using an avian embryo model
M Hagedorn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Medical progress - Management of cutaneous melanoma
H Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane
T Kuwana et al.
CELL (2002)
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
A Letai et al.
CANCER CELL (2002)
Death and anti-death: Tumour resistance to apoptosis
FH Igney et al.
NATURE REVIEWS CANCER (2002)
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma
GQ Phan et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)